

10 February 2025

## Patients Treated by the Dermatology Department with Dupilumab & Other Therapies

1. For patients treated by the Dermatology Department with Dupilumab in the latest four months (September to December 2024), could you please tell us:

a. How many patients were treated in the previous 4-month period (May to August 2024) with Dupilumab?

186

b. How many patients were treated in the previous 4-month period (May to August 2024) with any of the following advanced therapies:

Abrocitinib	7
Baricitinib	<5
Tralokinumab	<5
Upadacitinib	36
Lebrikizumab	8

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

c. How many patients were treated in the previous 4-month period (May to August 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?

Data not yet available due to the deployment of Encompass system.

d. How many patients were treated in the previous 4-month period (May to August 2024) with any other treatment (e.g. Acitretin, Alitretin, Pimecrolimus, Tacrolimus, oral corticosteroids , topical steroids)?

Data not yet available due to the deployment of Encompass system.

10 February 2025

**2. For patients treated by the Dermatology Department with Dupilumab in the four months from May to August 2024, could you please tell us:**

- a. How many patients were treated in the subsequent 4-month period (September to December 2024) with Dupilumab?**

205

- b. How many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following advanced therapies:**

<b>Abrocitinib</b>	7
<b>Baricitinib</b>	<5
<b>Tralokinumab</b>	<5
<b>Upadacitinib</b>	33
<b>Lebrikizumab</b>	9

We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act.

- c. How many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?**

Data not yet available due to the deployment of Encompass system.

- d. How many patients were treated in the subsequent 4-month period (September to December 2024) with any other treatment (e.g. Acitretin, Alitretin, Pimecrolimus, Tacrolimus, oral corticosteroids , topical steroids)?**

Data not yet available due to the deployment of Encompass system.